Baxalta Gmbh

The State University of New York

Brookhaven Science Associates, Lcc

Baxter International Inc.

Baxter Healthcare Sa

Baxter Vaccine Ag

Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Ian Livey

Brian A Crowe

Michael Schwendinger

Maria O'Rourke

Friedrich Dorner

John J Dunn

Benjamin J Luft

Brian Crowe

Maria O'rourke

P Noel Barrett

Nina Wressnigg

Gerald Aichinger

Noel P Barrett

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Chimeric OspA genes, proteins and methods of use thereof

Chimeric OspA proteins and methods of use thereof

Compositions comprising chimeric OSPA molecules and methods of use thereof

Chimeric OspA genes, proteins, and methods of use thereof

The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains ofare grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.

Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.

Immunogenic formulation of OSPC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

An effective immunogen against Lyme borreliosis in mammals comprises homogenous,pC protein and a physiologically-acceptable excipient.

Vaccine for the prevention of lyme disease

A method of purifying B. burgdorferi proteins comprising the steps of (a) disrupting a B. burgdorferi cell and fractionating the disrupted cell into membrane and cytoplasmic components; (b) resuspending the membrane component in a non-denaturing detergent thereby producing a solubilized protein and an insolubilized material and then separating said solubilized protein from said insolubilized material; (c) subjecting the solubilized protein to ion-exchange chromatography so as to produce protein fractions; and (d) assaying the protein fractions to identify those fractions which contain proteins of interest wherein the purified proteins of interest are in a biologically active form suitable for use in vaccines, is disclosed.

Method for the purification of PC protein from Borrelia burgdorferi

Growing community of inventors

Vienna, Austria

Ian Livey